Wearable Infusion Systems
|発行||Greystone Research Associates||商品コード||339370|
The increasing number of drugs that must be infused is creating a new class of drug delivery devices - devices that can deliver therapeutic drugs in volumes up to 10 mL and higher to ambulatory patients. Wearable subcutaneous infusion systems are targeting the growing need for administering biologicals - a segment that includes monoclonal antibodies, immune modulators and blood factors - that are indicated for chronic conditions. These devices distinguish themselves from syringes and injectors by delivering drug volumes in excess of 1-2 mL for durations that are measured in minutes rather than seconds. Several products in this device class have already reached the market, and recent agreements between device suppliers and pharma companies validate the market need that wearable infusion systems address. We expect wearable infusion systems to achieve and sustain double digit unit growth through the end of the decade.
The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
Therapeutic drugs consisting of proteins and peptides present unique drug packaging and delivery challenges. Often the dosing volume required to achieve a therapeutic effect requires the drug to be delivered via infusion, resulting in logistical, cost and safety issues. Drug developers and their delivery technology partners are attempting to address this limitation. The development of wearable devices capable of delivering drug volumes of 2 mL or higher subcutaneously is one promising method. This report examines this new class of devices and analyzes their potential impact on global drug deliver markets through the end of the decade.
Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.